What happened with SRPT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Sarepta Therapeutics sells medicines for people with Duchenne muscular dystrophy. EXONDYS 51, VYONDYS 53 and AMONDYS 45 help cells skip specific parts of genetic instructions so they can produce a shortened, functional dystrophin protein; each treats patients with particular mutations. ELEVIDYS delivers genetic material intended to produce a smaller functional version of that protein. These two treatment approaches drive its product sales, with exon-skipping medicines contributing slightly more than ELEVIDYS.
Distributors and specialty pharmacies sell and distribute its U.S. products to patients, while access depends partly on government and private-insurer coverage and reimbursement. Two customers account for a substantial share of product revenue. Sarepta retains U.S. rights to ELEVIDYS; Roche holds exclusive rights outside the U.S. and pays Sarepta through their collaboration, purchases of commercial supply and royalties.
The business depends on external manufacturers. Catalent supports ELEVIDYS production, and Sarepta has only one source for its drug substance and finished drug manufacturing. It also has contractual batch-payment obligations even if certain batches are not manufactured.
Regulatory limits narrow the patients it can treat. ELEVIDYS’s U.S. indication excludes patients who cannot walk, carries a boxed warning for acute liver injury and liver failure, and contraindicates use in patients with deletions in exon 8 or 9. Continued accelerated approval depends on confirmatory evidence of clinical benefit; the ESSENCE trial for VYONDYS 53 and AMONDYS 45 did not meet its primary endpoint, leaving their approval path unresolved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Sarepta’s results hinge on Duchenne treatment uptake and ELEVIDYS safety: watch Roche for its ex-U.S. ELEVIDYS rights, Catalent for manufacturing support and Nippon Shinyaku for exon-skipping competition.
Dyne Therapeutics is developing muscle-directed RNA medicines for Duchenne and myotonic dystrophy type 1 (DM1) that compete with Sarepta’s sold exon-skipping drugs and licensed neuromuscular RNA-interference programs. Dyne had no commercial products at December 31, 2025, so its Duchenne and DM1 development progress matters more to Sarepta than current sales.
Solid Biosciences is developing SGT-003 as a Duchenne gene-therapy alternative to Sarepta’s marketed ELEVIDYS. SGT-003’s development and safety news are the relevant comparison for ELEVIDYS, rather than sales from Solid’s investigational portfolio.
REGENXBIO challenges Sarepta both through RGX-202, its investigational Duchenne gene therapy competing with ELEVIDYS, and patent claims over technology allegedly used to manufacture ELEVIDYS. An appeals court revived the manufacturing-patent case on February 20, 2026, so litigation developments matter alongside RGX-202’s progress.
Sarepta depends on Arrowhead for licensed rare-disease drug programs and a platform that turns down target genes, known as RNA interference, as well as drug-substance manufacturing and testing. Progress in the licensed muscle, central-nervous-system and lung programs is the Arrowhead news most directly relevant to Sarepta’s siRNA portfolio.
Wave Life Sciences’ investigational WVE-N531 targets the same Duchenne patients whose mutations are amenable to exon 53 skipping as Sarepta’s sold VYONDYS 53. Watch WVE-N531’s development rather than Wave’s collaboration revenue for a read on competition facing VYONDYS 53.
Entrada Therapeutics is developing Duchenne drugs that overlap the mutation-defined patient groups served by Sarepta’s sold exon-skipping treatments. Its ENTR-601-45 and ENTR-601-51 programs are the ones to watch against AMONDYS 45 and EXONDYS 51, respectively.
Capricor Therapeutics’ Deramiocel could compete with or complement Sarepta’s Duchenne treatments: its investigational cell therapy targets inflammation and scarring behind muscle deterioration, rather than restoring dystrophin. Deramiocel’s approval and skeletal- and cardiac-function results are the relevant signals for Sarepta, not evidence of a direct replacement for its mutation-targeted drugs.
PTC Therapeutics earns sales from Translarna and Emflaza for Duchenne, serving the same disease market as Sarepta through different treatment approaches. Those two medicines’ sales are the relevant part of PTC’s results to compare with Sarepta’s Duchenne business.
BioMarin’s investigational BMN 351 targets Duchenne patients amenable to exon 51 skipping, the same group served by Sarepta’s sold EXONDYS 51. BioMarin’s sales mostly come from other diseases, so BMN 351’s progress is more useful for judging this competitive threat than its overall revenue.
uniQure competes with Sarepta beyond Duchenne, developing Huntington’s disease treatments against Sarepta’s investigational siRNA approach. Its Huntington’s program uses a virus to deliver gene-silencing RNA, so progress there is the relevant comparison for Sarepta’s Huntington’s program.
PepGen’s PGN-EDODM1 competes with ARO-DM1, the Arrowhead-origin program licensed to Sarepta, to treat the underlying cause of myotonic dystrophy type 1 (DM1). No therapy for that underlying cause was approved as of the filing, making PGN-EDODM1’s clinical progress the relevant signal rather than PepGen’s revenue, which was zero in 2025.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin's report can show how its BMN 351 candidate for exon-51 Duchenne is progressing, in the same patient group served by Sarepta's EXONDYS 51.
Watch BMN 351's trial progress and any reported clinical evidence, not BioMarin's overall sales. Continued trials with supportive evidence would make a future alternative for exon-51 patients more credible and sharpen the competitive threat to EXONDYS 51; a pause or weak evidence would leave that threat less established. The report would show how far the potential alternative has advanced, not whether patients have switched.
PTC Therapeutics, Inc. earningsPTCT
PTC Therapeutics' report will show sales of its Duchenne medicines Translarna and Emflaza, offering Sarepta a read on commercial demand in the same disease market.
Watch sales of Translarna and Emflaza rather than treating PTC Therapeutics' total revenue as a measure of the Duchenne market. Growth in those medicines would show continued commercial demand among the patient groups they reach; falling sales would signal pressure on uptake in those groups. Either way, this is a market comparison, not proof that Sarepta's sales will move in the same direction.
Sarepta Therapeutics,, Inc. earningsThis company
Sarepta's report will show whether ELEVIDYS sales can hold up after its label narrowed and some payers restricted coverage, while its three PMO exon-skipping drugs keep revenue steady.
Read ELEVIDYS sales alongside sales of the three PMO drugs. Steady or rising ELEVIDYS sales with steady PMO sales would show that eligible patients with coverage are sustaining the gene therapy without weakening the established products. A fall in ELEVIDYS sales would put that growth stream under pressure; if PMO sales also weaken, the strain reaches beyond ELEVIDYS. Together, the figures show whether Sarepta's commercial revenue base is holding up.
REGENXBIO Inc. earningsRGNX
REGENXBIO's report can show how its Duchenne gene therapy RGX-202 is progressing and whether the company reports movement in the patent case involving technology allegedly used to make ELEVIDYS.
Read RGX-202's clinical progress separately from the patent case. If the program advances with supportive evidence, ELEVIDYS faces a more credible potential rival; delays or weak evidence would make that product challenge less immediate. Separately, watch for case developments that could impede manufacturing or add legal burdens; progress in RGX-202 alone says nothing about the case's direction. Together, the two signals show whether Sarepta faces product competition, manufacturing risk, or both.
Wave Life Sciences Ltd. earningsWVE
Wave Life Sciences' report can show progress on its exon-53-skipping candidate WVE-N531, which targets the same Duchenne patient group as Sarepta's VYONDYS 53.
Watch WVE-N531's trial progress and reported clinical evidence, not Wave Life Sciences' collaboration revenue. Continued trials with supportive evidence would make a future option for exon-53 patients more credible and sharpen the competitive threat to VYONDYS 53; delays or weak evidence would leave that threat less established. The report reflects candidate progress, not patient switching.
PepGen Inc. earningsPEPG
PepGen's report can show progress on its DM1 candidate PGN-EDODM1, which competes with ARO-DM1, the program Sarepta licensed from Arrowhead.
Focus on PGN-EDODM1's clinical progress, not PepGen's revenue; the supplied company research says no therapy was approved to treat DM1's underlying cause. If PGN-EDODM1 advances with supportive evidence, the competitive challenge for ARO-DM1 becomes more concrete; if the program stalls or evidence is weak, that threat is less immediate. The report compares development progress, not patient use.
Arrowhead Research Corporation earningsARWR
Arrowhead's report can show progress in the rare-disease RNA-interference programs it licensed to Sarepta, giving readers a read on Sarepta's related pipeline.
Watch Arrowhead's updates on the rare-disease RNA-interference programs licensed to Sarepta, not Arrowhead's overall financial results as a proxy for Sarepta's. Progress would show that Sarepta's licensed pipeline is advancing; delays or setbacks would make its timing less certain. The conclusion is about the programs' development, not sales already earned by Sarepta.
